DocMorris AG (OTCMKTS:ZRSEF – Get Free Report) was the recipient of a large increase in short interest in the month of July. As of July 31st, there was short interest totaling 1,072,637 shares, an increase of 66.8% from the July 15th total of 643,190 shares. Based on an average daily trading volume, of 0 shares, the days-to-cover ratio is presently ∞ days.
Wall Street Analyst Weigh In
A number of brokerages have issued reports on ZRSEF. UBS Group raised shares of DocMorris from a “sell” rating to a “neutral” rating in a research note on Monday, July 20th. Deutsche Bank Aktiengesellschaft upgraded DocMorris from a “hold” rating to a “buy” rating in a report on Monday, July 13th. Two research analysts have rated the stock with a Buy rating and one has given a Hold rating to the stock. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy”.
Check Out Our Latest Stock Report on DocMorris
DocMorris Stock Performance
About DocMorris
DocMorris is a leading European online pharmacy brand and a subsidiary of the Swiss-based Zur Rose Group (OTCMKTS:ZRSEF). Through its digital platform, the company offers mail-order dispensing of prescription medications and over-the-counter health products directly to consumers’ homes.
The company’s core services include the online sale and delivery of prescription and non-prescription drugs, health supplements, personal care items and medical devices. Leveraging its e-commerce infrastructure and proprietary pharmacy management systems, DocMorris also provides digital health solutions such as telemedicine consultations, medication management tools and mobile app-based healthcare services.
Originally launched in the early 2000s in Germany, DocMorris has expanded its reach to serve customers in multiple European countries, including the Netherlands, Belgium, Luxembourg and Switzerland.
Featured Stories
- Five stocks we like better than DocMorris
- The AI Boom Is Turning This Cable Maker Into a Stock to Watch
- A Star Investor Just Trimmed Amazon—Here’s What It means
- Wendy’s Deal Buzz May Give Fast-Food Investors a New Reason to Look
- Home Depot Analysts See a Path to $375 and Beyond
Receive News & Ratings for DocMorris Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DocMorris and related companies with MarketBeat.com's FREE daily email newsletter.
